DOCSLIB.ORG

Raav-Based Gene Therapy for Molybdenum Cofactor Deficiency Type B" Has Been Written Independently with No Other Sources and Aids Than Quoted

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Raav-Based Gene Therapy for Molybdenum Cofactor Deficiency Type B rAAV-based gene therapy for molybdenum cofactor deficiency type B Doctoral thesis In partial fulfilment of the requirements for the degree "Doctor rerum naturalium (Dr. rer. nat.)" in the Molecular Medicine Study Program at the Georg-August University Göttingen submitted by Joanna Jakubiczka-Smorag born in Czestochowa, Poland Göttingen, 2015 Members of the Thesis Committee: Supervisor Prof. Dr. rer. nat. Peter Burfeind Institute of Human Genetics, University Medical Centre Göttingen Second member of the Thesis Committee Prof. Dr. rer. nat. Peter Schu Department of Cellular Biochemistry, University Medical Centre Göttingen Third member of the Thesis Committee Prof. Dr. med. Wolfgang Brück Institute of Neuropathology, University Medical Centre Göttingen Date of Disputation: 03.06.2015 AFFIDAVIT Herewith I declare that my doctoral thesis entitled: "rAAV-based gene therapy for molybdenum cofactor deficiency type B" has been written independently with no other sources and aids than quoted. Göttingen, 24.04.2015 ………………………………….. TABLE OF CONTENTS TABLE OF CONTENTS TABLE OF CONTENTS ........................................................................................................................... I LIST OF ABBREVIATIONS .................................................................................................................... VI 1 INTRODUCTION .......................................................................................................................... 1 1.1 Molybdenum cofactor (MoCo) deficiency ............................................................................ 1 1.2 Molybdenum cofactor (MoCo) ............................................................................................. 2 1.3 Characteristics of the MOCS2 gene ....................................................................................... 5 1.3.1 Genomic structure of the human MOCS2 and mouse Mocs2 genes ......................... 5 1.3.2 MOCS2 expression pattern......................................................................................... 7 1.4 MoCo-dependent enzymes ................................................................................................... 7 1.4.1 Aldehyde oxidase (AO) ............................................................................................... 7 1.4.2 Xanthine oxidoreductase (XOR) ................................................................................. 9 1.4.3 Sulphite oxidase (SO)................................................................................................ 11 1.4.4 Mitochondrial amidoxime reducing component (mARC) ........................................ 12 1.5 Substitution therapy for Molybdenum Cofactor Deficiency Type A ................................... 13 1.6 Gene therapy ....................................................................................................................... 13 1.6.1 Adeno-associated virus (AAV) .................................................................................. 15 1.6.2 Recombinant adeno-associated virus (AAV)-based gene therapy ........................... 18 1.7 AIMS .................................................................................................................................... 19 2 MATERIALS AND METHODS ..................................................................................................... 21 2.1 MATERIALS .......................................................................................................................... 21 2.1.1 Chemicals and reagents ........................................................................................... 21 2.1.2 Biochemical enzymes ............................................................................................... 24 2.1.3 Ready-to-use reaction systems ................................................................................ 24 2.1.4 Plasmids .................................................................................................................... 25 2.1.5 Usage ware ............................................................................................................... 25 2.1.6 Technical equipment ................................................................................................ 26 2.1.7 Solutions ................................................................................................................... 28 2.1.8 Culture media antibiotics and agar plates ............................................................... 30 2.1.8.1 Culture media for bacteria ............................................................................... 30 2.1.8.2 Culture media for eukaryotic cells ................................................................... 31 2.1.8.3 Antibiotics ......................................................................................................... 31 2.1.8.4 IPTG/X-Gal plates ............................................................................................. 31 2.1.9 Biological material .................................................................................................... 32 I TABLE OF CONTENTS 2.1.9.1 Bacterial strains ................................................................................................ 32 2.1.9.2 Eukaryotic cell lines .......................................................................................... 32 2.1.9.3 Mouse strains ................................................................................................... 32 2.1.10 Synthetic DNA oligonucleotides ............................................................................... 32 2.1.10.1 Vector-specific primer ...................................................................................... 32 2.1.10.2 Human-specific primers ................................................................................... 33 2.1.10.3 Mouse-specific primers .................................................................................... 33 2.1.10.4 Genotyping primers .......................................................................................... 34 2.1.10.5 cDNA synthesis primers .................................................................................... 35 2.1.11 Antibodies ................................................................................................................ 35 2.1.11.1 Primary antibodies ........................................................................................... 35 2.1.11.2 Secondary antibodies ....................................................................................... 35 2.1.12 Databases ................................................................................................................. 36 2.1.13 Statistical methods ................................................................................................... 37 2.1.14 Sterilisation of solutions and equipment ................................................................. 37 2.2 METHODS ............................................................................................................................ 37 2.2.1 Isolation and purification of nucleic acids ................................................................ 37 2.2.1.1 Minipreparation of plasmid DNA ..................................................................... 37 2.2.1.1.1 Preparation of bacterial glycerol stocks ...................................................... 38 2.2.1.2 Large-scale preparation of Endotoxin-free plasmid DNA using the Qiagen Maxi Kit .......................................................................................................................... 38 2.2.1.3 Isolation of genomic DNA ................................................................................. 38 2.2.1.3.1 Isolation of genomic DNA from tissue samples........................................... 38 2.2.1.3.2 Isolation of genomic DNA from cells ........................................................... 39 2.2.1.3.3 Isolation of genomic DNA from sperm ........................................................ 39 2.2.1.3.4 Isolation of genomic DNA from recombinant adeno-associated virus (rAAV) ..................................................................................................................... 40 2.2.1.4 Isolation of total RNA from tissue samples ...................................................... 40 2.2.1.5 Determination of nucleic acid concentration................................................... 40 2.2.1.6 Cloning techniques ........................................................................................... 40 2.2.1.6.1 Cleavage of DNA with restriction endonucleases ....................................... 40 2.2.1.6.2 Isolation of DNA fragments from agarose gels using the QIAquick Gel Extraction Kit (Qiagen) .................................................................................................... 41 2.2.1.6.3 Dephosphorylation of plasmid DNA ............................................................ 41 II TABLE OF CONTENTS 2.2.1.6.4 Ligation of DNA fragments .......................................................................... 41 2.2.1.6.5 TA-Cloning ................................................................................................... 42 2.2.1.6.6 Transformation of competent bacteria (Hanahan, 1983) ........................... 42 2.2.1.7 Gel electrophoresis .........................................................................................
Load more

Recommended publications
  • Supplemental Table S1
    Entrez Gene Symbol Gene Name Affymetrix EST Glomchip SAGE Stanford Literature HPA confirmed Gene ID Profiling profiling Profiling Profiling array profiling confirmed 1 2 A2M alpha-2-macroglobulin 0 0 0 1 0 2 10347 ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 1 0 0 0 0 3 10350 ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 1 0 0 0 0 4 10057 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1 0 0 0 0 5 10060 ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 1 0 0 0 0 6 79575 ABHD8 abhydrolase domain containing 8 1 0 0 0 0 7 51225 ABI3 ABI gene family, member 3 1 0 1 0 0 8 29 ABR active BCR-related gene 1 0 0 0 0 9 25841 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 1 0 1 0 0 10 30 ACAA1 acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-Coenzyme A thiol 0 1 0 0 0 11 43 ACHE acetylcholinesterase (Yt blood group) 1 0 0 0 0 12 58 ACTA1 actin, alpha 1, skeletal muscle 0 1 0 0 0 13 60 ACTB actin, beta 01000 1 14 71 ACTG1 actin, gamma 1 0 1 0 0 0 15 81 ACTN4 actinin, alpha 4 0 0 1 1 1 10700177 16 10096 ACTR3 ARP3 actin-related protein 3 homolog (yeast) 0 1 0 0 0 17 94 ACVRL1 activin A receptor type II-like 1 1 0 1 0 0 18 8038 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 1 0 0 0 0 19 8751 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 1 0 0 0 0 20 8728 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 1 0 0 0 0 21 81792 ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 1 0 0 0 0 22 9507 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • About the Existence of Common Determinants of Gene Expression In
    González-Prendes et al. BMC Genomics (2019) 20:518 https://doi.org/10.1186/s12864-019-5889-5 RESEARCH ARTICLE Open Access About the existence of common determinants of gene expression in the porcine liver and skeletal muscle Rayner González-Prendes1,6†, Emilio Mármol-Sánchez1†, Raquel Quintanilla2, Anna Castelló1,3, Ali Zidi1, Yuliaxis Ramayo-Caldas1, Tainã Figueiredo Cardoso1,4, Arianna Manunza1,ÁngelaCánovas1,5 and Marcel Amills 1,3* Abstract Background: The comparison of expression QTL (eQTL) maps obtained in different tissues is an essential step to understand how gene expression is genetically regulated in a context-dependent manner. In the current work, we have compared the transcriptomic and eQTL profiles of two porcine tissues (skeletal muscle and liver) which typically show highly divergent expression profiles, in 103 Duroc pigs genotyped with the Porcine SNP60 BeadChip (Illumina) and with available microarray-based measurements of hepatic and muscle mRNA levels. Since structural variation could have effects on gene expression, we have also investigated the co-localization of cis-eQTLs with copy number variant regions (CNVR) segregating in this Duroc population. Results: The analysis of differential expresssion revealed the existence of 1204 and 1490 probes that were overexpressed and underexpressed in the gluteus medius muscle when compared to liver, respectively (|fold- change| > 1.5, q-value < 0.05). By performing genome scans in 103 Duroc pigs with available expression and genotypic data, we identified 76 and 28 genome-wide significant cis-eQTLs regulating gene expression in the gluteus medius muscle and liver, respectively. Twelve of these cis-eQTLs were shared by both tissues (i.e.
    [Show full text]
  • Mouse Mtarc2 Conditional Knockout Project (CRISPR/Cas9)
    https://www.alphaknockout.com Mouse Mtarc2 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Mtarc2 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Mtarc2 gene (NCBI Reference Sequence: NM_133684.3 ; Ensembl: ENSMUSG00000073481 ) is located on Mouse chromosome 1. 8 exons are identified, with the ATG start codon in exon 1 and the TAG stop codon in exon 7 (Transcript: ENSMUST00000068725). Exon 3 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Mtarc2 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-221J17 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 3 starts from about 44.08% of the coding region. The knockout of Exon 3 will result in frameshift of the gene. The size of intron 2 for 5'-loxP site insertion: 7225 bp, and the size of intron 3 for 3'-loxP site insertion: 1143 bp. The size of effective cKO region: ~669 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 3 4 8 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Mtarc2 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats.
    [Show full text]
  • Protein-Protein Interactions of Human Mitochondrial Amidoxime-Reducing Component in Mammalian Cells John Thomas
    Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Fall 1-1-2016 Protein-Protein Interactions of Human Mitochondrial Amidoxime-Reducing Component in Mammalian Cells John Thomas Follow this and additional works at: https://dsc.duq.edu/etd Recommended Citation Thomas, J. (2016). Protein-Protein Interactions of Human Mitochondrial Amidoxime-Reducing Component in Mammalian Cells (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/61 This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact [email protected]. PROTEIN-PROTEIN INTERACTIONS OF HUMAN MITOCHONDRIAL AMIDOXIME- REDUCING COMPONENT IN MAMMALIAN CELLS A Dissertation Submitted to the Bayer School of Natural and Environmental Sciences Duquesne University In partial fulfillment of the requirements for the degree of Doctor of Philosophy By John A. Thomas December 2016 Copyright by John A. Thomas October 2016 PROTEIN-PROTEIN INTERACTIONS OF HUMAN MITOCHONDRIAL AMIDOXIME-REDUCING COMPONENT IN MAMMALIAN CELLS By John A. Thomas Approved October 24, 2016 ____________________________________ ____________________________________ Partha Basu, PhD Michael Cascio, PhD Professor of Chemistry and Biochemistry Associate Professor of Chemistry and (Committee Chair) Biochemistry (Committee Member) ____________________________________
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Hereditary Spastic Paraplegia: from Genes, Cells and Networks to Novel Pathways for Drug Discovery
    brain sciences Review Hereditary Spastic Paraplegia: From Genes, Cells and Networks to Novel Pathways for Drug Discovery Alan Mackay-Sim Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia; a.mackay-sim@griffith.edu.au Abstract: Hereditary spastic paraplegia (HSP) is a diverse group of Mendelian genetic disorders affect- ing the upper motor neurons, specifically degeneration of their distal axons in the corticospinal tract. Currently, there are 80 genes or genomic loci (genomic regions for which the causative gene has not been identified) associated with HSP diagnosis. HSP is therefore genetically very heterogeneous. Finding treatments for the HSPs is a daunting task: a rare disease made rarer by so many causative genes and many potential mutations in those genes in individual patients. Personalized medicine through genetic correction may be possible, but impractical as a generalized treatment strategy. The ideal treatments would be small molecules that are effective for people with different causative mutations. This requires identification of disease-associated cell dysfunctions shared across geno- types despite the large number of HSP genes that suggest a wide diversity of molecular and cellular mechanisms. This review highlights the shared dysfunctional phenotypes in patient-derived cells from patients with different causative mutations and uses bioinformatic analyses of the HSP genes to identify novel cell functions as potential targets for future drug treatments for multiple genotypes. Keywords: neurodegeneration; motor neuron disease; spastic paraplegia; endoplasmic reticulum; Citation: Mackay-Sim, A. Hereditary protein-protein interaction network Spastic Paraplegia: From Genes, Cells and Networks to Novel Pathways for Drug Discovery. Brain Sci. 2021, 11, 403.
    [Show full text]
  • ZFYVE27 (S-15): Sc-132148
    SAN TA C RUZ BI OTEC HNOL OG Y, INC . ZFYVE27 (S-15): sc-132148 BACKGROUND APPLICATIONS Zinc finger FYVE domain-containing protein 27 (ZFYVE27), also known as ZFYVE27 (S-15) is recommended for detection of ZFYVE27 isoforms 1-5 of SPG33, is a 411 amino acid member of the FYVE-finger family of proteins. mouse, rat and human origin by Western Blotting (starting dilution 1:200, The FYVE domain is a cysteine-rich domain of about 70 amino acids that dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, plays a role in the endosomal localization of the FYVE-finger proteins, and dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, a majority of these proteins serve as regulators of endocytic membrane traf - dilution range 1:30-1:3000); non cross-reactive with other ZFYVE family ficking. ZFYVE27, a multi-pass membrane protein, is an endosomal protein members. that binds to Spastin, a protein that is primarily involved in microtubule dy- ZFYVE27 (S-15) is also recommended for detection of ZFYVE27 isoforms 1-5 namics and severing, vesicular trafficking and endosomal trafficking. Muta- in additional species, including bovine. tions in the gene encoding ZFTVE27 affect neuronal intracellular trafficking in the corticospinal tract and are thought to lead to hereditary spastic para - Suitable for use as control antibody for ZFYVE27 siRNA (h): sc-90825, plegia (HSP), a neurodegenerative disorder, characterized by progressive ZFYVE27 siRNA (m): sc-155606, ZFYVE27 shRNA Plasmid (h): sc-90825-SH, paralysis of the legs, which is caused by impaired axonal transport.
    [Show full text]
  • Download Ppis for Each Single Seed, Thus Obtaining Each Seed’S Interactome (Ferrari Et Al., 2018)
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.14.425874; this version posted January 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias Nikoleta Vavouraki1,2, James E. Tomkins1, Eleanna Kara3, Henry Houlden3, John Hardy4, Marcus J. Tindall2,5, Patrick A. Lewis1,4,6, Claudia Manzoni1,7* Author Affiliations 1: Department of Pharmacy, University of Reading, Reading, RG6 6AH, United Kingdom 2: Department of Mathematics and Statistics, University of Reading, Reading, RG6 6AH, United Kingdom 3: Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom 4: Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom 5: Institute of Cardiovascular and Metabolic Research, University of Reading, Reading, RG6 6AS, United Kingdom 6: Department of Comparative Biomedical Sciences, Royal Veterinary College, London, NW1 0TU, United Kingdom 7: School of Pharmacy, University College London, London, WC1N 1AX, United Kingdom *Corresponding author: [email protected] Abstract The Hereditary Spastic Paraplegias are a group of neurodegenerative diseases characterized by spasticity and weakness in the lower body. Despite the identification of causative mutations in over 70 genes, the molecular aetiology remains unclear. Due to the combination of genetic diversity and variable clinical presentation, the Hereditary Spastic Paraplegias are a strong candidate for protein- protein interaction network analysis as a tool to understand disease mechanism(s) and to aid functional stratification of phenotypes.
    [Show full text]
  • Staphylococcus Epidermidis Rights Reserved; Exclusive Licensee Protects Against Skin Neoplasia American Association for the Advancement 1 1 1 2 2 of Science
    SCIENCE ADVANCES | RESEARCH ARTICLE HEALTH AND MEDICINE Copyright © 2018 The Authors, some A commensal strain of Staphylococcus epidermidis rights reserved; exclusive licensee protects against skin neoplasia American Association for the Advancement 1 1 1 2 2 of Science. No claim to Teruaki Nakatsuji, Tiffany H. Chen, Anna M. Butcher, Lynnie L. Trzoss, Sang-Jip Nam, * original U.S. Government 1 3 3 4 2 1† Karina T. Shirakawa, Wei Zhou, Julia Oh, Michael Otto, William Fenical, Richard L. Gallo Works. Distributed under a Creative We report the discovery that strains of Staphylococcus epidermidis produce 6-N-hydroxyaminopurine (6-HAP), a mol- Commons Attribution ecule that inhibits DNA polymerase activity. In culture, 6-HAP selectively inhibited proliferation of tumor lines but did NonCommercial not inhibit primary keratinocytes. Resistance to 6-HAP was associated with the expression of mitochondrial amidoxime License 4.0 (CC BY-NC). reducing components, enzymes that were not observed in cells sensitive to this compound. Intravenous injection of 6-HAP in mice suppressed the growth of B16F10 melanoma without evidence of systemic toxicity. Colonization of mice with an S. epidermidis strain producing 6-HAP reduced the incidence of ultraviolet-induced tumors compared to mice colonized by a control strain that did not produce 6-HAP. S. epidermidis strains producing 6-HAP were found in the metagenome from multiple healthy human subjects, suggesting that the microbiome of some individuals may confer protection against skin cancer. These findings show a new role for skin commensal bacteria in host defense. INTRODUCTION (17, 18). More recently, several strains of S. epidermidis, S.
    [Show full text]
  • A Missense Variant in Mitochondrial Amidoxime Reducing Component 1 Gene and Protection Against Liver Disease
    bioRxiv preprint doi: https://doi.org/10.1101/594523; this version posted March 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease Connor A. Emdin, DPhil, Mary Haas, PhD, Amit V. Khera, MD, Krishna Aragam, MD, Mark Chaffin, MS, Lan Jiang, MS, Wei-Qi Wei, MD PhD, Qiping Feng, PhD, Juha Karjalainen, PhD, Aki Havulinna, DSc, Tuomo Kiiskinen, MD, Alexander Bick, MD, Diego Ardissino, MD, James G. Wilson, MD, Heribert Schunkert, MD, Ruth McPherson, MD, Hugh Watkins, MD PhD, Roberto Elosua, MD PhD, Matthew J Bown, FRCS, Nilesh J Samani, FRCP, Usman Baber, MD, Jeanette Erdmann, PhD, Namrata Gupta, PhD, John Danesh FRCP DPhil, Danish Saleheen, MBBS PhD, Mark Daly, PhD, Joshua Denny, MD, Stacey Gabriel, PhD, Sekar Kathiresan, MD Corresponding Author: Sekar Kathiresan, MD Center for Genomic Medicine Massachusetts General Hospital 185 Cambridge Street, CPZN 5.830 Boston, MA 02114 Email: [email protected] Phone: 617 643 6120 Author Affiliations 1) Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114 (Emdin, Khera, Aragam, Haas, Bick, Kathiresan) 2) Department of Medicine, Harvard Medical School, Boston, MA 02114 (Khera, Aragam, Haas, Emdin, Kathiresan) 3) Program in Medical and Population Genetics, Broad Institute,
    [Show full text]
  • Hereditary Spastic Paraplegias: Clinical Spectrum in Sudan, Further Deciphering of the Molecular Bases of Autosomal Recessive Forms and New Genes Emerging
    Hereditary spastic paraplegias : clinical spectrum in Sudan, further deciphering of the molecular bases of autosomal recessive forms and new genes emerging Liena Elbaghir Omer Elsayed To cite this version: Liena Elbaghir Omer Elsayed. Hereditary spastic paraplegias : clinical spectrum in Sudan, further deciphering of the molecular bases of autosomal recessive forms and new genes emerging. Neurons and Cognition [q-bio.NC]. Université Pierre et Marie Curie - Paris VI; University of Khartoum, 2016. English. NNT : 2016PA066056. tel-01438739 HAL Id: tel-01438739 https://tel.archives-ouvertes.fr/tel-01438739 Submitted on 18 Jan 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Université Pierre et Marie Curie University of Khartoum Cerveau-Cognition-Comportement (ED3C) Institut du Cerveau et de la Moelle Epinière / Equipe Bases Moléculaires, Physiopathologie Et Traitement Des Maladies Neurodégénératives Hereditary spastic paraplegias: clinical spectrum in Sudan, further deciphering of the molecular bases of autosomal recessive forms and new genes emerging
    [Show full text]